Boston, Massachusetts 02215

  • Metastatic Breast Cancer

Purpose:

This research is evaluating the impact of a 12-week prolonged nightly fasting (POF) and exercise intervention on metabolic markers and patient reported outcomes in women with metastatic breast cancer (MBC) initiating endocrine therapy in combination with palbociclib or alpelisib.


Study summary:

This is single-arm feasibility pilot study exploring whether a combined prolonged nightly fasting (POF) and exercise program could impact hyperglycemia and other adverse metabolic consequences of PI3 kinase inhibitors in women with metastatic breast cancer (MBC). Women who exercise regularly and who have lower levels of blood sugar and metabolic hormones like insulin have a lower risk of developing breast cancer. Some evidence also suggests that exercise and metabolism are related to cancer recurrence in women who are diagnosed with breast cancers that can be removed with surgery, but less is known about how exercise and metabolic factors are related to cancer progression in women whose cancer has advanced beyond the breast and underarm lymph nodes. This study is designed to look at the effects of exercise combined with prolonged nightly fasting (having a longer time between dinner and breakfast the next day), on blood sugar and hormones that control metabolism. This study looks to provide important information about whether making these kinds of changes is possible for women living with advanced breast cancer and will explore how making these changes effects blood sugar and hormone levels in women taking different kinds of treatments for advanced breast cancer. The research study procedures include screening for eligibility, a baseline visit to collect information about diet and exercise habits, a baseline blood draw, participation in a 12-week diet and exercise program, and a follow up visit and blood collection at the end of the diet and exercise program. Participants will be in this research study for up to 14-weeks, including the baseline and end of study visits to collect study measures. It is expected that about 30 people will take part in this research study


Criteria:

Inclusion Criteria: - Diagnosis of ER and/or PR+ metastatic or locally unresectable breast cancer - Postmenopausal (including concurrent use of ovarian suppression) - Initiating endocrine therapy in combination with: - Cohort 1: alpelisib - Cohort 2: palbociclib - Self-reported ability to walk two blocks - > 18 years of age - Approval from treating oncologist, confirmed via email or in writing - Ability to read and understand English Exclusion Criteria: - Diagnosis of diabetes requiring medication - Engaging in >90 minutes of moderate or vigorous physical activity per week


NCT ID:

NCT04708860


Primary Contact:

Principal Investigator
Jennifer Ligibel, MD
Dana-Farber Cancer Institute

Jennifer Ligibel, MD
Phone: 617.632.3800
Email: Jennifer_Ligibel@dfci.harvard.edu


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02215
United States

Jennifer Ligibel, MD
Phone: 617-632-3800
Email: Jennifer_Ligibel@dfci.harvard.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.